A multi-institutional team of investigators reported this week in Science Translational Medicine on a new antiviral drug candidate that inhibits a broad range of coronaviruses, including the SARS and...

Orlando-based specialty pharmaceutical company, Profounda announced it has received the US Food and Drug Administration’s Orphan Drug Designation for the use of Impavido (miltefosine) to treat Granulomatous...

A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment. About 60 percent of patients nationwide are prescribed antibiotic eye drops, even though antibiotics...

Melinta Therapeutics announced Monday that the U.S. Food and Drug Administration (FDA) has approved Baxdela™ (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure...

Scientists from Rutgers University-New Brunswick, the biotechnology company NAICONS Srl., and elsewhere have discovered a new antibiotic effective against drug-resistant bacteria: pseudouridimycin. The...

To win the war against antibiotic resistant super bugs, scientists seek to find the origin of resistance genes. Further, they try to identify how the genes are introduced to disease-causing bacteria –...

GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced positive results from two phase III studies of tafenoquine, an investigational 8-aminoquinoline, for the prevention of relapse...

On Thursday, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful...

New data presented today at ASM Microbe 2017 showed that Paratek Pharmaceuticals, Inc.’s Phase 3 antibiotic omadacycline is highly active against common bacterial pathogens in acute skin and skin structure...

According to the Centers for Disease Control and Prevention (CDC), on any given day, about one in 25 hospital patients has at least one healthcare-associated infection (HAI). Clearly, HAIs are a huge problem...